title: Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
authors: Waleed
authors: W
authors: Ghanima
authors: Soo Y
authors: SY
authors: Lee
authors: Sarah
authors: S
authors: Barsam
authors: Allison
authors: A
authors: Miller
authors: Per M
authors: PM
authors: Sandset
authors: James B
authors: JB
authors: Bussel
mesh_terms: D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011961:Receptors, Fc / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D019851:Thrombophilia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D013926:Thrombopoietin / Q000009:adverse effects / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D001565:Benzoates; D005338:Fibrin Fibrinogen Degradation Products; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C036309:fibrin fragment D; C082218:MPL protein, human; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag